Heron Patrick J bought $199,994 worth of shares (21,052 units at $9.50) (SEC Form 4)

$ARQT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARQT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Heron Patrick J

(Last) (First) (Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300

(Street)
WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2024 P 21,052 A $9.5 8,785,284 I By Frazier Life Sciences VIII, L.P.(1)
Common Stock 7 I By FHM Life Sciences VIII, L.L.C.(2)
Common Stock 23,688 I By The Heron Living Trust 11/30/2004(3)
Common Stock 8,687(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares are held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
2. The shares are held directly by FHM Life Sciences VIII, L.L.C. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
3. The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
4. Includes 4,375 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.
/s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron 03/06/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ARQT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARQT

DatePrice TargetRatingAnalyst
12/30/2024$19.00Buy
H.C. Wainwright
8/28/2024$15.00Buy
Jefferies
1/3/2024$4.00 → $8.00Neutral → Buy
Mizuho
10/26/2023$57.00 → $4.00Buy → Neutral
Mizuho
10/13/2023$32.00 → $6.00Buy → Neutral
Goldman
9/7/2022$46.00Buy
Needham
3/17/2022$45.00Buy
Goldman
3/2/2022$35.00 → $37.00Overweight
Morgan Stanley
More analyst ratings

$ARQT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

    WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025. Details for the company's participation are as follows:        Fireside Chat Date: Tuesday, April 8, 2025        Fireside Chat Time: 11:00 am EDT The webcast for this conference may be accessed at the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

    Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease controlRapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) Success at week 4, with significant improvements seen as early as week 1 Demonstrated efficacy and tolerability in treating facial involvement in AD, which affected 42% of trial participantsShown to deliver sustained improvement in disease control for up to 56 weeks of treatmentTORONTO, March 17, 2025 /CNW/ - Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful inno

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

    Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatmentsNew patient reported outcome data for investigational ZORYVE® (roflumilast) foam 0.3% demonstrated favorable efficacy, safety, and local tolerability data in scalp and body psoriasisIn the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and children, with more than half experiencing involvement of the scalp WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE)

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARQT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARQT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARQT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARQT
SEC Filings

See more

$ARQT
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARQT
Leadership Updates

Live Leadership Updates

See more
  • Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

    Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcutis Announces Leadership Transition

    Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

    WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company. "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a le

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARQT
Financials

Live finance-specific insights

See more
  • Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returnsFull Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United StatesS

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

    Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product revenue for the full-year 2024 is expected to be approximately $160 million, up approximately 449% vs. 2023Robust unit growth across the portfolio with gross-to-net (GTN) similar to prior quarterPreliminary unaudited cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024 are expected to be approximately $229 millionCompany to release complete fourth quarter and full year 2024 financial results and host a conference call and webcast on February 25, 2025 at 4:30 p.

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

    Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth of 452% vs. Q3 '23 and 45% vs. Q2 '24Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 50 percent range, improving from the high 50 percent range last quarterSustained growth in prescriptions for both cream and foam, with total U.S. franchise unit demand increase of 25% quarter over quarterSupplemental New Drug Application (sNDA) for ZORYVE foam accepted by Food & Drug Administration (FDA) for the treatment of scalp and body psoriasis in adults and adolesc

    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARQT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more